Portal Login:
  • Clients
  • Providers
  • Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar
  • Skip to footer
    Portal Login:
  • Clients
  • Providers
  • About MCN
  • Careers
  • MCNTalk
  • Contact Us

MCN | Medical Consultants Network

The Power of a Second Look

  • Services
    • Independent Medical Examinations
    • Medical Peer Reviews
    • Bill Review Services
    • Utilization Reviews
  • Expertise
    • Short and Long-Term Disability
    • Workers’ Compensation
    • Auto/PIP/Casualty/Liability
    • Independent Review Organization Services
  • For Clients
  • For Providers
  • Your Exam
    • About Your Exam
    • About Your External Review
    • Contact & Scheduling
  • Schedule Now
  • About MCN
  • MCNTalk
  • Careers
  • Contact Us

MCNTalk
News, Insights & Opinions

Home / MCNTalk / A Further Look at Insys Therapeutics and the Dangers of Fent...

July 8, 2016

A Further Look at Insys Therapeutics and the Dangers of Fentanyl

As a follow-up to yesterday’s blog post regarding the dangerous drug Fentanyl and the inappropriate marketing by Insys Therapeutics to increase its sales, the following article from Southern Investigative Reporting Foundation is a worthwhile read. Pharmaceutical companies’ compensating physicians for discussing their product is a longstanding, and legal, practice. It wasn’t until 2013 that concerns were raised within the medical community and regulations were put in place to ensure disclosure of all physician payments. However, another unremarked-upon issue is the nature in which potentially dangerous prescriptions such as Fentanyl are prescribed. Doctors are not heavily constrained by the law to restrict whether drugs can be prescribed for reasons other than what they are designed for. In the case of Fentanyl, data from the Food and Drug Administration shows that Subsys (a Fentanyl spray) is proving lethal to a growing number of patients who are taking it for reasons beyond what the drug was designed for. The article further delves into studies that have been done showing adverse events resulting in deaths since Subsys was approved by the FDA in January 2012. The overwhelming question is how a company like Insys can continue to grow exponentially despite this sort of data. This article tackles this question, taking a close look at Insys’ sales force and the leading prescribers at the center of serious allegations regarding their prescription-writing practices.

Share this:

  • Twitter
  • Email
  • More
  • Facebook
  • Reddit
  • Print

Leave a Comment

Previous Post
Next Post

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Recent Posts

  • The Quality Divide: What Makes a Quality IME Physician?
  • The Quality Divide: Is Your Vendor Driving IME Excellence?
  • The Quality Divide: When and How to Request an IME?
  • April Clinic Calendars Are Available
  • MCN’s Client Portal Login Page is Changing

Archives

Footer


  • Twitter
  • LinkedIn

Quick Links

  • Services
  • Expertise
  • About MCN
  • Careers

Division Headquarters

MCN
1200 5th Ave., Ste. 650
Seattle, WA 98101

See all offices

Email Us

General Inquiries: info@mcn.com
Sales & Marketing: marketing@mcn.com

Call Us

206.343.6100
800.248.6269

© Copyright 2023 Mitchell International, Inc. All Rights Reserved.

  • Privacy Policy
  • Sitemap